Cargando…
Acute Myeloid Leukemia in Qatar (2010–2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes
The current study retrospectively evaluated cytogenetic profiles, various prognostic factors, and survival outcomes in 128 acute myeloid leukemia (AML) patients (14 ≤ age ≤ 70 years) admitted to the National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, between...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313235/ https://www.ncbi.nlm.nih.gov/pubmed/32625233 http://dx.doi.org/10.3389/fgene.2020.00553 |
_version_ | 1783549909320859648 |
---|---|
author | El Omri, Halima Taha, Ruba Yasin Elomri, Adel Kacem, Nancy Elsabah, Hesham Ellahie, Anil Yousaf Gamil, Amna Ibrahim, Firyal Soliman, Dina Sameh Abdelrahman El Akiki, Susanna Jane Lawson Nawaz, Zafar Al Sabbagh, Ahmad El Omri, Abdelfatteh |
author_facet | El Omri, Halima Taha, Ruba Yasin Elomri, Adel Kacem, Nancy Elsabah, Hesham Ellahie, Anil Yousaf Gamil, Amna Ibrahim, Firyal Soliman, Dina Sameh Abdelrahman El Akiki, Susanna Jane Lawson Nawaz, Zafar Al Sabbagh, Ahmad El Omri, Abdelfatteh |
author_sort | El Omri, Halima |
collection | PubMed |
description | The current study retrospectively evaluated cytogenetic profiles, various prognostic factors, and survival outcomes in 128 acute myeloid leukemia (AML) patients (14 ≤ age ≤ 70 years) admitted to the National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, between January 2010 and December 2016. The median age at diagnosis was 43 years, and 80% were less than 60 years old; 75% of patients were male. Cytogenetic analysis was integrated into the World Health Organization 2008 classification and showed that the percentages of normal and abnormal karyotypes were similar, accounting for 48.4% of each group of patients. The AML risk stratification based on cytogenetic analysis resulted in the following distribution: 18% in the favorable risk group, 57% in the intermediate-risk group, 24% in the unfavorable risk group, and 1% unknown. Only 88 patients received therapy with curative intent; 67% achieved complete remission, increasing to 81% after inductions 1 and 2. The median overall survival (OS) and disease-free survival (DFS) in AML patients were 26.6 and 19.5 months, respectively. The 3-year OS and DFS were 40 and 36%, respectively. Prognostic factors including age, gender, white blood cell count, and risk stratification were not significantly associated with treatment outcomes, whereas response to treatment vs. failure was significantly associated with the outcome (p = 0.01). The current study supports the importance of cytogenetics as a useful tool in diagnosis, prognosis, and risk assessment in AML treatment. |
format | Online Article Text |
id | pubmed-7313235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73132352020-07-02 Acute Myeloid Leukemia in Qatar (2010–2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes El Omri, Halima Taha, Ruba Yasin Elomri, Adel Kacem, Nancy Elsabah, Hesham Ellahie, Anil Yousaf Gamil, Amna Ibrahim, Firyal Soliman, Dina Sameh Abdelrahman El Akiki, Susanna Jane Lawson Nawaz, Zafar Al Sabbagh, Ahmad El Omri, Abdelfatteh Front Genet Genetics The current study retrospectively evaluated cytogenetic profiles, various prognostic factors, and survival outcomes in 128 acute myeloid leukemia (AML) patients (14 ≤ age ≤ 70 years) admitted to the National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, between January 2010 and December 2016. The median age at diagnosis was 43 years, and 80% were less than 60 years old; 75% of patients were male. Cytogenetic analysis was integrated into the World Health Organization 2008 classification and showed that the percentages of normal and abnormal karyotypes were similar, accounting for 48.4% of each group of patients. The AML risk stratification based on cytogenetic analysis resulted in the following distribution: 18% in the favorable risk group, 57% in the intermediate-risk group, 24% in the unfavorable risk group, and 1% unknown. Only 88 patients received therapy with curative intent; 67% achieved complete remission, increasing to 81% after inductions 1 and 2. The median overall survival (OS) and disease-free survival (DFS) in AML patients were 26.6 and 19.5 months, respectively. The 3-year OS and DFS were 40 and 36%, respectively. Prognostic factors including age, gender, white blood cell count, and risk stratification were not significantly associated with treatment outcomes, whereas response to treatment vs. failure was significantly associated with the outcome (p = 0.01). The current study supports the importance of cytogenetics as a useful tool in diagnosis, prognosis, and risk assessment in AML treatment. Frontiers Media S.A. 2020-06-17 /pmc/articles/PMC7313235/ /pubmed/32625233 http://dx.doi.org/10.3389/fgene.2020.00553 Text en Copyright © 2020 El Omri, Taha, Elomri, Kacem, Elsabah, Ellahie, Gamil, Ibrahim, Soliman, El Akiki, Nawaz, Al Sabbagh and El Omri. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics El Omri, Halima Taha, Ruba Yasin Elomri, Adel Kacem, Nancy Elsabah, Hesham Ellahie, Anil Yousaf Gamil, Amna Ibrahim, Firyal Soliman, Dina Sameh Abdelrahman El Akiki, Susanna Jane Lawson Nawaz, Zafar Al Sabbagh, Ahmad El Omri, Abdelfatteh Acute Myeloid Leukemia in Qatar (2010–2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes |
title | Acute Myeloid Leukemia in Qatar (2010–2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes |
title_full | Acute Myeloid Leukemia in Qatar (2010–2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes |
title_fullStr | Acute Myeloid Leukemia in Qatar (2010–2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes |
title_full_unstemmed | Acute Myeloid Leukemia in Qatar (2010–2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes |
title_short | Acute Myeloid Leukemia in Qatar (2010–2016): Clinical, Biological, and Prognostic Factors and Treatment Outcomes |
title_sort | acute myeloid leukemia in qatar (2010–2016): clinical, biological, and prognostic factors and treatment outcomes |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7313235/ https://www.ncbi.nlm.nih.gov/pubmed/32625233 http://dx.doi.org/10.3389/fgene.2020.00553 |
work_keys_str_mv | AT elomrihalima acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT taharubayasin acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT elomriadel acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT kacemnancy acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT elsabahhesham acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT ellahieanilyousaf acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT gamilamna acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT ibrahimfiryal acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT solimandinasamehabdelrahman acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT elakikisusannajanelawson acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT nawazzafar acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT alsabbaghahmad acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes AT elomriabdelfatteh acutemyeloidleukemiainqatar20102016clinicalbiologicalandprognosticfactorsandtreatmentoutcomes |